Advertisement
Imaging
Subscribe to Imaging
View Sample

FREE Email Newsletter

Varian Medical Systems Management to Present at Lazard Capital Markets 7th Annual Healthcare Conference

November 5, 2010 7:38 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Nov. 5, 2010 /- Varian Medical Systems (NYSE: VAR ) is scheduled to present at Lazard Capital Markets Healthcare Conference at 9:30 a.m. ET on Wednesday, November 17th at the St. Regis Hotel in New York City. Participating executives will include Elisha Finney, senior...

Business-to-Business Magazine Names Orion HealthCorp CEO as Top 25 Entrepreneur for 2010

November 4, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Nov. 4, 2010 /- Orion HealthCorp , Inc., a leader in medical billing and practice management for more than 20 years, announced today that its President and CEO, Terrence L. Bauer, has been named to Business-to-Business Magazine's 2010 Top 25 Entrepreneur list. Bauer ranked No. 12...

SPO Announces Completion of Rebranding Program

November 4, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

SPO Announces Completion of Rebranding Program -- NEW YORK, November 4, 2010 /-

Advertisement

Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results

November 4, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, Nov. 4, 2010 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) announces third quarter financial results for 2010. The merger of Biovail Corporation (Legacy Biovail) and Valeant Pharmaceuticals International (Legacy Valeant) was completed on...

Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan

November 4, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, Nov. 4, 2010 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) today announced that the Company's Board of Directors (the "Board") has declared a one-time special dividend of US$1.00 per common share (the "Special Dividend") that shareholders of...

Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program

November 4, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, Nov. 4, 2010 /- Stereotaxis, Inc. (Nasdaq: STXS ) announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.  The program targets...

Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System

November 4, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., Nov. 4, 2010 /- Interventional Spine®, Inc. today announced that the United States Patent Office has issued U.S. Patent No. 7,824,429, entitled Method and Apparatus for Spinal Fixation.  This patent includes 43 claims that provide key patent protection for the...

Cocrystal Discovery Receives Awards for Its Novel Antiviral Drug Development Programs

November 3, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Nov. 3, 2010 /- Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified...

Advertisement

PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy

November 3, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Nov. 3, 2010 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani released the following statement and video regarding the mid-term election: Watch the Video "Congratulations to all of the candidates who...

Research Facility Expansion Will Create, Retain More than 150 Jobs in Chester County

November 3, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

HARRISBURG, Pa., Nov. 3, 2010 /PRNewswire-USNewswire/ -- A global contract research organization will expand its operations in Chester County and create more than 80 new jobs within three years, the Department of Community and Economic Development announced today. PPD Inc. is planning to...

IRS Awards $244,479 Grant to STB Lifesaving Technologies®

November 3, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

ROCKVILLE, Md., Nov. 3, 2010 /- STB Lifesaving Technologies ® today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. government in the amount of $244,479.   The Qualifying Therapeutic Discovery Project was included in the...

Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania

November 3, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

BASKING RIDGE, N.J., Nov. 3, 2010 /- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at IMPACT 2010 held at...

Champions Biotechnology Awarded $1.46 million in Grants

November 3, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, Nov. 3, 2010 /- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR ), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today received $1.46 million in grants as part of the Qualifying...

Advertisement

ACR Distributes Free High-Tech Mammography Education Tool to NY Facilities

November 3, 2010 10:33 am | by Bio-Medicine.Org | News | Comments

RESTON, Va., Nov. 3, 2010 /PRNewswire-USNewswire/ -- The American College of Radiology (ACR) distributed 1,500 copies of the College's Mammography Case Review ( MCR5 ) educational CD-ROM free of charge to physicians in approximately 600 ACR-accredited mammography facilities throughout New...

Asia Pacific Pharma Companies Turning to High-Risk, High-Reward Drug Development, According to New Report from Thomson Reuters

November 2, 2010 11:33 pm | by Bio-Medicine.Org | News | Comments

PHILADELPHIA and LONDON, Nov. 3, 2010 /- Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development, according to a new report released today by CMR...

Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects

November 2, 2010 7:34 pm | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Nov. 2, 2010 /- Telik, Inc. (Nasdaq: TELK ) a clinical stage drug development company focused on developing drugs to treat cancer, announced that it has been awarded grants totaling $1,222,396 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP)....

New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs

November 2, 2010 12:36 pm | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO, Nov. 2, 2010 /- Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion...

Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010

November 2, 2010 12:36 pm | by Bio-Medicine.Org | News | Comments

COLORADO SPRINGS, Colo., Nov. 2, 2010 /- Cannabis Science, Inc. (OTC Bulletin Board: CBIS ), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce to its shareholders and the investment community that its Board of Directors have confirmed...

Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial

November 2, 2010 12:35 am | by Bio-Medicine.Org | News | Comments

Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial -- CARMIEL, Israel, Nov. 2, 2010 /-

Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program

November 2, 2010 12:35 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Nov. 2, 2010 /- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has been awarded $977,917 in grants under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act. The...

Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study

November 1, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

BEDFORD, Mass., Nov. 1, 2010 /- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the...

Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning

November 1, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Nov. 1, 2010 /- At this year's Annual Meeting of the American Society for Radiation Oncology (ASTRO), Royal Philips Electronics (NYSE: PHG, AEX: PHI) is demonstrating how the integration of imaging and treatment planning can help simplify the clinician and patient experience....

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD

November 1, 2010 1:34 am | by Bio-Medicine.Org | News | Comments

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results Fro...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®

November 1, 2010 1:34 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Nov. 1, 2010 /- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for Pixuvri® (pixantrone dimaleate) as monotherapy for the treatment of adult...

Track Down Awarepoint at AMSUS 116th Annual Meeting

October 31, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 31 /- WHO: Awarepoint , a provider of ZigBee-based real-time location solutions ( RTLS ) for hospitals, will exhibit in Booth #215 during AMSUS, the Society of the Federal Health Agencies. WHAT: Stop by and meet with Vice Admiral Harold Koenig, M.D. (retired) along with...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading